EFFECT OF VAL66MET BDNF ALLELIC POLYMORPHISM ON DYNAMICS OF THE BDNF SERUM LEVEL AND PERFORMANCEOF THE RAVEN’S TEST IN PATIENTS WITH STROKE
Introduction.Study of the influence of molecular and genetic predisposition to forecast neurorehabilitation patients with stroke is of
great scientific and practical importance.
The aim of the study.Determining the impact of allelic polymorphism Val66Met BDNF on the dynamics of the cognitive functioning and
maintenance of brain-derived neurotrophic factor in the peripheral blood of patients with stroke.
Methods. The sample included 186 patients with stroke, allelic polymorphism was determined by polymerase chain reaction. In 140
(75,3%) Met
–
(ValVal) genotype was detected, Met
+
(Val/Met
+
MetMet) – in 46 (24,7%). Depending on the duration of disease, subjects
were divided into 4 groups - group 1: less than 1 year; group 2: from 1 to 2 years; group 3: from 2 to 4 years; group 4: 4 years or more.
Results. Averages content BDNF, determined by the method of enzyme-linked immunosorbent assay in the serum of patients with
genotype Met
–
was: 29,3±1,0 ng/ml; 25,2±1,6 ng/ml; 24,1±1,4 ng/ml, 22,8±1,2 ng/ml. In patients with Met
+
genotype was: 22,4±2,2 ng/
ml; 25,4±1,7 ng/ml; 21,9±2,1 ng/ml; 21,5±0,5 ng/ml. Average Raven’s test score in patients with Met–
genotype (evaluation in points):
71,0±4,1; 86,0±4,8; 74,1±4,2; 74,6±5,0. In the Met
+
group: 69,3±6,6; 73,0±6,2; 77,0±4,3; 65,0±4,1 ng/ml.
Conclusions. The data suggest that the Met
–
genotype provides higher compensatory and adaptive capacities of central nervous system
in patients with stroke. The integrated assessment of the studied parameters is needed.
Keywords:
stroke, genes, brain-derived neurotrophic factor, a Raven’s test